FDA Clearance Tracker · P200013
Alinity m HBV
Last checked: Nov 20, 2026Latest source record: Aug 29, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Aug 29, 2020
Approved (reclassified)
Time to decision
180 days
Received Mar 2, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P200013
- Device name
- Alinity m HBV
- Applicant
- Abbott Molecular, Inc.
- Applicant location
- Des Plaines, IL
- Received
- Mar 2, 2020
- Decided
- Aug 29, 2020
- Decision
- Approved (reclassified)
- Supplements
- 26 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Hepatitis Viral B DNA Detection (MKT)
- Device class
- Class II
- Regulation
- 21 CFR 866.3174
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Alinity m HBV. The Alinity m HBV assay is an in vitro polymerase chain reaction (PCR) with fluorescent labeled probes assay for use with the automated Alinity m System to quantitate Hepatitis B Virus (HBV) DNA in human plasma and serum. The Alinity m HBV assay is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy. The assay can be used to measure HBV DNA levels at baseline and during treatment to aid in assessing response to treatment. The results from the Alinity m HBV assay must be interpreted within the context of all relevant clinical and laboratory findings.This assay is not intended to be used in screening blood, blood products, or cell, tissue, and cellular and tissue-based products (HCT/Ps), or as a diagnostic test to confirm the presence of HBV infection.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MKT. The earliest in FDA's data is P050028, decided Sep 4, 2008.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Molecular, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alinity m HCV510(k)
K252102 · Decided Sep 25, 2025 · 84 days after receipt
Device type: Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus (MZP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.